Sight Sciences Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
186
- Stock Symbol
-
SGHT
- Share Price
-
$10.19
- (As of Friday Closing)
Sight Sciences General Information
Description
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Contact Information
Website
www.sightsciences.comCorporate Office
- 4040 Campbell Avenue
- Suite 100
- Menlo Park, CA 94025
- United States
Corporate Office
- 4040 Campbell Avenue
- Suite 100
- Menlo Park, CA 94025
- United States
Sight Sciences Stock Performance
As of 20-Nov-2026, Sight Sciences’s stock price is $10.19. Its current market cap is $566M with 55.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.19 | $10.62 | $3.38 - $11.60 | $566M | 55.6M | 311K | -$0.52 |
Sight Sciences Financials Summary
As of 30-Sep-2026, Sight Sciences has a trailing 12-month revenue of $88.4M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 477,845 | 367,585 | 100,170 | 141,723 |
| Revenue | 88,395 | 77,363 | 79,866 | 81,056 |
| EBITDA | (22,766) | (32,787) | (45,897) | (49,415) |
| Net Income | (28,398) | (38,426) | (51,507) | (55,547) |
| Total Assets | 104,948 | 115,300 | 142,839 | 166,651 |
| Total Debt | 42,106 | 40,775 | 40,362 | 35,414 |
Sight Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sight Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sight Sciences Comparisons
Industry
Financing
Details
Sight Sciences Competitors (10)
One of Sight Sciences’s 10 competitors is Glaukos, a Formerly VC-backed company based in Aliso Viejo, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Glaukos | Formerly VC-backed | Aliso Viejo, CA | ||||
| Nova Eye Medical | Corporation | Kent Town, Australia | ||||
| New World Medical | Corporation | Rancho Cucamonga, CA | ||||
| Keranova | Venture Capital-Backed | Saint-Étienne, France | ||||
| MicroSurgical Technology | Corporate Backed or Acquired | Redmond, WA |
Sight Sciences Patents
Sight Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025248489-A1 | Bio-erodible ocular implants for treatment of conditions of the eye | Pending | 29-May-2024 | ||
| US-20250352055-A1 | Systems for eye treatment | Pending | 17-May-2024 | ||
| WO-2025239981-A1 | Systems for eye treatment | Pending | 17-May-2024 | ||
| US-20250268752-A1 | Intraocular systems, devices, kits, and methods | Pending | 27-Feb-2024 | ||
| WO-2025181734-A1 | Intraocular systems, devices, kits, and methods | Pending | 27-Feb-2024 | A61F9/00781 |
Sight Sciences Signals
Sight Sciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.21 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Sight Sciences FAQs
-
When was Sight Sciences founded?
Sight Sciences was founded in 2010.
-
Where is Sight Sciences headquartered?
Sight Sciences is headquartered in Menlo Park, CA.
-
What is the size of Sight Sciences?
Sight Sciences has 186 total employees.
-
What industry is Sight Sciences in?
Sight Sciences’s primary industry is Surgical Devices.
-
Is Sight Sciences a private or public company?
Sight Sciences is a Public company.
-
What is Sight Sciences’s stock symbol?
The ticker symbol for Sight Sciences is SGHT.
-
What is the current stock price of Sight Sciences?
As of 20-Nov-2026 the stock price of Sight Sciences is $10.19.
-
What is the current market cap of Sight Sciences?
The current market capitalization of Sight Sciences is $566M.
-
What is Sight Sciences’s current revenue?
The trailing twelve month revenue for Sight Sciences is $88.4M.
-
Who are Sight Sciences’s competitors?
Glaukos, Nova Eye Medical, New World Medical, Keranova, and MicroSurgical Technology are some of the 10 competitors of Sight Sciences.
-
What is Sight Sciences’s annual earnings per share (EPS)?
Sight Sciences’s EPS for 12 months was -$0.52.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process